Search

everythinglearnresearchcommunity

for

Search:↓

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

An imbalance between certain immune cells is linked to a chronic skin condition and may be influenced by obesity, smoking, and autoimmune issues.

Peptides improve skin health and treatments for hair loss and pregnancy-related skin issues are evolving.

Smart microneedles using advanced tech could improve psoriasis treatment.

Clofazimine effectively treated ashy dermatosis in a patient.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Dupilumab effectively treated severe alopecia areata in a child.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

IL-23 inhibitors may help treat other skin conditions, but more research is needed.

Switching from infliximab to Ustekinumab improved both hair loss and Crohn's symptoms in the patient.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Dupilumab improves eczema in Netherton Syndrome but not ichthyosis linearis circumflexa.